Ariad

Ariad honored for its new drug

ARIAD Reports Positive Early Phase 2 Results on AP23573, Novel mTOR Inhibitor, in Patients with Advanced    Sarcomas at ASCO; Data Show Clinical Benefit and Symptomatic Improvement

Products in the Pipeline at Ariad

 

Chemokine

Chemokine Vancouver, Canada

IDM

IDM: Maker of Junovan for Ostesoarcoma

 

Scancell

Scancell: Using Immunology to Fight Cancer

 

Topotarget

Topotarget Makers of HSP90 inhibitors

Other

AMDL

Immune responses to the 105AD7 human anti-idiotypic vaccine after intensive chemotherapy, for osteosarcoma

QED Bioscience Inc.